Application of Antidepressant Therapy in Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2021.09.007
- Author:
Weifang SHANG
1
;
Songfei LI
1
;
Zhanyue NIU
1
;
Fang GU
1
;
Qifei WANG
2
Author Information
1. Department of Gastroenterology, Peking University Third Hospital
2. Department of Psychiatry, Beijing Zhaode Hospital
- Publication Type:Journal Article
- Keywords:
Colitis, Ulcerative;
Crohn Disease;
Depression;
Inflammatory Bowel Disease;
Therapy
- From:
Chinese Journal of Gastroenterology
2021;26(9):560-563
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of inflammatory bowel disease (IBD) is increasing year by year, yet lacking specific treatment, which seriously affects patients' health and quality of life. The pathogenesis of IBD has not been fully clarified, the psycho-neuro-endocrine-immune regulation through gut-brain axis may play an important role in the pathogenesis of IBD. Studies have shown that IBD patient has an increased risk of depression. More than 20% of IBD patients have depression, the incidence is about 2-4 times that of general population. Antidepressant therapy has good efficacy in some IBD patients. The possible mechanism includes affecting the gut-brain axis, inhibiting inflammation, improving mood, etc. However, there are few relevant studies, and the value of antidepressant therapy in the treatment of IBD needs to be further confirmed by large-sample randomized controlled studies. This article reviewed the application of antidepressant therapy in IBD.
